Tango Therapeutics, Inc.
TNGX•NASDAQ•Healthcare•Biotechnology

About Tango Therapeutics

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOBarbara Weber
Founded2014
Employees155
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.tangotx.com
Phone857 320 4900
Address
201 Brookline Avenue, Suite 901 Boston, Massachusetts 02215 United States

Corporate Identifiers

CIK0001819133
CUSIP87583X109
ISINUS87583X1090
SIC2834

Leadership Team & Key Executives

Dr. Barbara L. Weber M.D.
President, Chief Executive Officer and Director
Daniella Beckman CPA
Chief Financial Officer
Douglas J. Barry Esq., J.D.
Chief Compliance Officer and Corporate Secretary
Dr. Adam S. Crystal M.D., Ph.D.
President of Research and Development
Prof. Alan Ashworth FRS, Ph.D.
Founder and Member of Scientific Advisory Board
Dr. William G. Kaelin Jr., M.D.
Founder and Member of Scientific Advisory Board
Dr. Antoni Ribas M.D., Ph.D.
Founder and Member of Scientific Advisory Board
Dr. Michael Palmieri Ph.D.
Chief Technical Operations Officer
Jannik N. Andersen Ph.D.
Chief Scientific Officer
Elizabeth Pingpank Hickin
Vice President of IR and Corporate Communications